Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Eli Lilly And Co (LLY) Price & Performance

MicroSectors FANG and Innovation 3X Leveraged ETNTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

MicroSectors FANG and Innovation 3X Leveraged ETN vs Eli Lilly And Co — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $32.38, while Eli Lilly And Co trades at $1,221.8 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none. Which is the better fit depends on your goals.

FNGULLY
Sector
Leveraged / InverseHealth
52-Week High
$36.15$1.24K
52-Week Low
$13.73$639.43
Market Cap
$1.08T
Enterprise Value
$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MicroSectors FANG and Innovation 3X Leveraged ETN

FNGU (MicroSectors FANG+ 3X Leveraged ETN) trades at $32.45, down 3.71% today, reflecting the inherent volatility of leveraged products. Technical indicators show a bullish moving average trend but neutral oscillators, with RSI levels suggesting overbought conditions. Recent news highlights significant downside volatility, including a 16% single-session drop on June 5, 2026, underscoring the risks of 3x leverage on tech stocks.

The outlook for FNGU remains highly speculative, driven by Nasdaq-100 volatility rather than company fundamentals. Investment opportunities exist for aggressive traders betting on tech rallies, but risks include amplified losses during market downturns and structural decay from daily rebalancing. Caution is warranted given the product's design for short-term trading.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MicroSectors FANG and Innovation 3X Leveraged ETN

FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.

Read more on FNGU

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY